Market Cap 4.55B
Revenue (ttm) 949.25M
Net Income (ttm) 64.09M
EPS (ttm) N/A
PE Ratio 42.74
Forward PE 38.27
Profit Margin 6.75%
Debt to Equity Ratio 0.51
Volume 273,200
Avg Vol 264,852
Day's Range N/A - N/A
Shares Out 35.97M
Stochastic %K 7%
Beta 1.45
Analysts Strong Sell
Price Target $163.00

Company Profile

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. It operates in two segments, Automation Enabling Technologies and Medical Solutions. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast...

Industry: Scientific & Technical Instruments
Sector: Technology
Phone: 781 266 5700
Address:
125 Middlesex Turnpike, Bedford, United States
Dauphinoise
Dauphinoise Jul. 2 at 5:58 PM
$NOVT Slowly but surely back up to $180 🙏🏻
0 · Reply
True_Alpha
True_Alpha Jun. 27 at 9:16 PM
$NOVT Strong Close.. Sometimes being patient is greedy
0 · Reply
Money_Flow_Trader_
Money_Flow_Trader_ Jun. 27 at 5:39 PM
$NOVT up 28% since April.. Stalkin entry, daily flow undervalued
0 · Reply
Estimize
Estimize May. 14 at 10:00 AM
Wall St is expecting 0.73 EPS for $NOVT Q2 [Reporting 08/12 BMO] http://www.estimize.com/intro/novt?chart=historical&metric_name=eps&utm_co
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 5:28 AM
$NOVT Digging the precision tech play. Medical and industrial markets looking solid. New product launches could be catalyst. Watching closely for Q1 performance and potential entry point. standout article: https://beyondspx.com/article/novanta-inc-novt-a-consistent-performer-in-the-medical-and-advanced-industrial-markets
0 · Reply
Dauphinoise
Dauphinoise Mar. 12 at 10:18 AM
$NOVT Yikes, where’s the bounce?!
0 · Reply
AVTradeGlobal
AVTradeGlobal Mar. 5 at 9:10 PM
$NOVT On the history, the green harmonic zone demonstrated itself as a reliable support zone. If the price reaches it, there is a high probability of an upward bounce. #NOVT #StockMarket #TechnicalAnalysis #Market
0 · Reply
JarvisFlow
JarvisFlow Mar. 3 at 1:00 PM
Baird has adjusted their stance on Novanta ( $NOVT ), setting the rating to Neutral with a target price of 169 → 160.
0 · Reply
d_risk
d_risk Feb. 25 at 8:07 PM
$NOVT - Novanta Inc. Common Stock - 10K - Updated Risk Factors NOVT's 2025 risk factors emphasize challenges from future pandemics, political conditions, scaling manufacturing, international tariffs, and increased outsourcing risks. New risks include medical device regulations, cybersecurity compliance, and internal controls, while inflationary pressures and patent infringement remain concerns. #Risk https://d-risk.ai/NOVT/10-K/2025-02-25
0 · Reply
briefingcom
briefingcom Feb. 25 at 2:24 PM
$NOVT: Novanta beats by $0.05, reports revs in-line; guides Q1 EPS below estimate, revs below estimate; guides FY25 EPS below consensus, revs below two analyst estimate https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250225070354NOVT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Latest News on NOVT
Novanta Inc. (NOVT) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:50 PM EDT - 2 months ago

Novanta Inc. (NOVT) Q1 2025 Earnings Call Transcript


Novanta Announces Financial Results for the First Quarter 2025

May 6, 2025, 7:00 AM EDT - 2 months ago

Novanta Announces Financial Results for the First Quarter 2025


Novanta Inc. (NOVT) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 3:36 PM EST - 5 months ago

Novanta Inc. (NOVT) Q4 2024 Earnings Call Transcript


Novanta Inc. (NOVT) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 1:47 PM EST - 9 months ago

Novanta Inc. (NOVT) Q3 2024 Earnings Call Transcript


Novanta Announces Financial Results for the Third Quarter 2024

Nov 5, 2024, 6:59 AM EST - 9 months ago

Novanta Announces Financial Results for the Third Quarter 2024


Novanta Inc. (NOVT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 2:45 PM EDT - 1 year ago

Novanta Inc. (NOVT) Q2 2024 Earnings Call Transcript


Novanta Inc. (NOVT) Q1 2024 Earnings Call Transcript

May 7, 2024, 3:48 PM EDT - 1 year ago

Novanta Inc. (NOVT) Q1 2024 Earnings Call Transcript


Novanta Inc. (NOVT) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 3:52 PM EST - 1 year ago

Novanta Inc. (NOVT) Q4 2023 Earnings Call Transcript


Novanta completes acquisition of Motion Solutions

Jan 2, 2024, 4:15 PM EST - 1 year ago

Novanta completes acquisition of Motion Solutions


Novanta announces agreement to acquire Motion Solutions

Nov 14, 2023, 4:13 PM EST - 1 year ago

Novanta announces agreement to acquire Motion Solutions


Novanta, Inc. (NOVT) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:23 PM EST - 1 year ago

Novanta, Inc. (NOVT) Q3 2023 Earnings Call Transcript


Novanta receives Silver rating from EcoVadis

Jul 27, 2023, 5:00 PM EDT - 2 years ago

Novanta receives Silver rating from EcoVadis


Novanta Inc. (NOVT) Q1 2023 Earnings Call Transcript

May 14, 2023, 6:12 AM EDT - 2 years ago

Novanta Inc. (NOVT) Q1 2023 Earnings Call Transcript


Novanta: The Valuation Seems Way Too High

Mar 20, 2023, 2:48 PM EDT - 2 years ago

Novanta: The Valuation Seems Way Too High


Novanta Inc. (NOVT) Q4 2022 Earnings Call Transcript

Mar 1, 2023, 4:01 PM EST - 2 years ago

Novanta Inc. (NOVT) Q4 2022 Earnings Call Transcript


Dauphinoise
Dauphinoise Jul. 2 at 5:58 PM
$NOVT Slowly but surely back up to $180 🙏🏻
0 · Reply
True_Alpha
True_Alpha Jun. 27 at 9:16 PM
$NOVT Strong Close.. Sometimes being patient is greedy
0 · Reply
Money_Flow_Trader_
Money_Flow_Trader_ Jun. 27 at 5:39 PM
$NOVT up 28% since April.. Stalkin entry, daily flow undervalued
0 · Reply
Estimize
Estimize May. 14 at 10:00 AM
Wall St is expecting 0.73 EPS for $NOVT Q2 [Reporting 08/12 BMO] http://www.estimize.com/intro/novt?chart=historical&metric_name=eps&utm_co
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 5:28 AM
$NOVT Digging the precision tech play. Medical and industrial markets looking solid. New product launches could be catalyst. Watching closely for Q1 performance and potential entry point. standout article: https://beyondspx.com/article/novanta-inc-novt-a-consistent-performer-in-the-medical-and-advanced-industrial-markets
0 · Reply
Dauphinoise
Dauphinoise Mar. 12 at 10:18 AM
$NOVT Yikes, where’s the bounce?!
0 · Reply
AVTradeGlobal
AVTradeGlobal Mar. 5 at 9:10 PM
$NOVT On the history, the green harmonic zone demonstrated itself as a reliable support zone. If the price reaches it, there is a high probability of an upward bounce. #NOVT #StockMarket #TechnicalAnalysis #Market
0 · Reply
JarvisFlow
JarvisFlow Mar. 3 at 1:00 PM
Baird has adjusted their stance on Novanta ( $NOVT ), setting the rating to Neutral with a target price of 169 → 160.
0 · Reply
d_risk
d_risk Feb. 25 at 8:07 PM
$NOVT - Novanta Inc. Common Stock - 10K - Updated Risk Factors NOVT's 2025 risk factors emphasize challenges from future pandemics, political conditions, scaling manufacturing, international tariffs, and increased outsourcing risks. New risks include medical device regulations, cybersecurity compliance, and internal controls, while inflationary pressures and patent infringement remain concerns. #Risk https://d-risk.ai/NOVT/10-K/2025-02-25
0 · Reply
briefingcom
briefingcom Feb. 25 at 2:24 PM
$NOVT: Novanta beats by $0.05, reports revs in-line; guides Q1 EPS below estimate, revs below estimate; guides FY25 EPS below consensus, revs below two analyst estimate https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250225070354NOVT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
DonCorleone77
DonCorleone77 Feb. 25 at 12:32 PM
$NOVT Novanta sees FY25 adjusted EPS $3.35-$3.55, consensus $3.79 Sees FY25 revenue $1B, consensus $1.04B. "We continue to see strength in our medical business and reconfirm our outlook for incremental new product sales in 2025, the majority of which sell into hospital operating room and surgical equipment," said Matthijs Glastra. "Although capital spending in industrial, semiconductor, and life science is expected to remain volatile in the first half of the year due to trade war uncertainty, government funding, and geopolitical disruptions, there continues to be strong signs of growth slowly recovering. While we are optimistic about stronger revenue growth in these markets, our initial full-year guidance will remain conservative until these growth trends strengthen. Therefore, our full year revenue guidance is based on delivering $50 million of incremental new product sales, primarily in the medical technology markets, and presumes no market recoveries in the capital spending markets in industrial, semiconductor, and life science at this time."
0 · Reply
DonCorleone77
DonCorleone77 Feb. 25 at 12:32 PM
$NOVT Novanta sees Q1 EPS 63c-71c, consensus 78c Sees Q1 revenue $232M-$236M, consensus $244.89M. The company said, "For the first quarter of 2025, the Company expects GAAP revenue of approximately $232 million to $236 million. The Company expects Adjusted Gross Profit Margin to be in the range of 46.0% to 46.5%. The Company expects Adjusted EBITDA to be in the range of $48 million to $51 million and Adjusted Diluted EPS to be in the range of $0.63 to $0.71. The Company's guidance assumes no significant changes in foreign exchange rates."
0 · Reply
DonCorleone77
DonCorleone77 Feb. 25 at 12:31 PM
$NOVT Novanta reports Q4 adjusted EPS 76c, consensus 71c Reports Q4 revenue $238.06M, consensus $240.29M. "Novanta achieved solid financial results for the full year 2024, effectively navigating a persistently challenging environment," said Matthijs Glastra, chair and CEO. "We had strong operating performance, achieving above our expectations for Adjusted Gross Margins and Adjusted EBITDA, and also excellent cash flow generation, while also returning to organic growth in the Fourth Quarter. In the year, we delivered and launched multiple new products which are on schedule to ramp in 2025. The fundamentals of Novanta are strong, and we remain confident in our strategy, in our portfolio, our exposure to diversified end-markets, and in our ability to generate strong operating cash flows to compound our growth through our targeted acquisition strategy."
0 · Reply
Dauphinoise
Dauphinoise Feb. 24 at 8:20 PM
$NOVT I do hope it’s good news tomorrow! 🤣
0 · Reply
Estimize
Estimize Feb. 19 at 12:06 AM
Wall St is expecting 0.71 EPS for $NOVT Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/novt?chart=historical&metric_name=eps&utm_co
0 · Reply
Dauphinoise
Dauphinoise Feb. 14 at 7:50 PM
$NOVT Can’t catch a break…
0 · Reply
Estimize
Estimize Feb. 12 at 11:00 AM
Wall St is expecting 0.78 EPS for $NOVT Q1 [Reporting 05/13 BMO] http://www.estimize.com/intro/novt?chart=historical&metric_name=eps&utm_co
0 · Reply
Dauphinoise
Dauphinoise Jan. 23 at 2:35 PM
$NOVT Anything…🙄
0 · Reply
Dauphinoise
Dauphinoise Dec. 17 at 5:22 PM
$NOVT Well this has been a shitty investment in the last year compared to the rest of the market 🙄
0 · Reply
CarolSmith308
CarolSmith308 Dec. 10 at 4:10 PM
$NOVT AITX’s focus on recurring revenue provides a stable foundation for innovative growth strategies.
0 · Reply
Estimize
Estimize Nov. 28 at 11:00 AM
Wall St is expecting 0.71 EPS for $NOVT Q4 [Reporting 02/26 BMO] http://www.estimize.com/intro/novt?chart=historical&metric_name=eps&utm_co
0 · Reply
insiderbuyingselling
insiderbuyingselling Nov. 9 at 8:54 AM
$NOVT new insider selling: 3660 shares. http://insiderbuyingselling.com/?t=NOVT
0 · Reply